MedTrace Logo

Bone Turnover in Type 2 Diabetes and Non-diabetes Controls (DiaMarv)

NCT05585697 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2023-11-29

No results posted yet for this study

Summary

Type 2 diabetes (T2D) is related to an increased risk of major fractures which does written in English. The summary is used not only increase society health care costs, but also increase the morbidity and in the recruitment of peer reviewers.: mortality for patients with T2D. Traditional fracture predictors underestimate the risk in T2D. Thus, the bone affection is not caused by decreased bone mineral density but rather by impaired bone quality leading to fragile bone. In diabetes, circulating bone turnover markers are suppressed and advanced glycation endproducts may accumulate in the tissue. The study aims at exploring whether bone turnover in T2D is compromised in the circulation, bone marrow, and bone tissue and whether advanced glycation endproducts accumulate in these tissues. Furthermore, the investigators will assess whether bone turnover markers predict fractures in a cohort of individuals with diabetes. The project will contribute to the knowledge on bone disease in T2D and will ultimately benefit the patients by improving future fracture prevention strategies.

Conditions

  • Diabetes Mellitus, Type 2
  • Bone Fragile

Interventions

OTHER

None - crossectional

None - crossectional

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585697 on ClinicalTrials.gov